CIRI · Inserm U1111 · Lyon
Leukemia & Lymphoma Immune Biology
We study how lymphoid and myeloid malignancies escape the immune system, and we turn that biology into tools clinicians can actually use.
About the team
L2IB is a research team of the CIRI — Centre International de Recherche en Infectiologie in Lyon, France (Inserm U1111 · CNRS UMR5308 · ENS de Lyon · Université Claude Bernard Lyon 1), co-led by Laurent Genestier and Emmanuel Bachy.
Forty-three people — 25 full-time equivalents — work at the interface of fundamental immunology, haematology and computational biology. We combine primary patient samples, functional immunology, mouse models and machine learning on large clinical cohorts to understand lymphomagenesis and to improve how patients are diagnosed, stratified and treated.
The team is based on the Lyon Sud campus and works in close collaboration with the clinical haematology and pathology departments of the Hospices Civils de Lyon.
What we do
Epigenetics
Chromatin alterations in T-cell lymphoma, and ATAC-seq protocols that work on routine FFPE material.
Environment & genomics
BTG1 mutations, MCL1 sensitivity, and how glyphosate exposure shapes lymphoma risk and chemoresistance.
Microenvironment
Metabolism and the bone marrow niche in paediatric B-ALL, from pre-leukaemic clones to relapse.
Inflammation
The IL-1 axis in myeloid malignancies, and the first PDX model of VEXAS syndrome.
Cell therapy
Determinants of CAR-T efficacy and toxicity, and anti-CD4 CAR-T cells for T-cell malignancies.
Omics & AI
A transversal computational programme feeding every axis — and the source of our open tools.
In numbers
| People · full-time equivalents | 43 · 25 |
| Publications, 2019–2024 | 480+, of which 127 in journals with IF > 10 |
| Grants raised, 2019–2023 | 5.1 M€ across 68 grants, coordinator in 61 |
| Secured for 2024–2028 | 1.47 M€ |
| Licensed patents | 1 |
Highlights
- FIBOM-AI — a machine-learning tool predicting grade 2–3 bone marrow fibrosis from a routine complete blood count, trained on nearly 2,000 patients across French university hospitals.
- BTG1 mutations sensitise lymphomas to MCL1 inhibitors — Delage et al., Blood, 2023, protected by patent WO2023057484A1.
- First PDX model of VEXAS syndrome, with and without associated MDS.
- Member of the CALYM Carnot Institute.
Contact
L2IB — CIRI
Faculté de Médecine Lyon Sud Charles Mérieux
165 Chemin du Grand Revoyet, 69310 Pierre-Bénite, France